secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0001213900-24-106554
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Cary Claiborne signs new 3-year deal at Adial; bonus target raised to 50%, 350K option grant
--------------------------------------------------------------------------------

- New three-year employment agreement effective Dec 5, 2024, replaces prior agreement from Dec 2021.
- Base salary remains $489,250; annual bonus target increased to 50% of base salary.
- Granted 350,000 stock options vesting pro rata monthly over 36 months.
- Agreement provides for severance and change-in-control protections per detailed terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024106554/0001213900-24-106554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024106554/ea0223975-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-106554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer